QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NYSE:BIO

Bio-Rad Laboratories Stock Forecast, Price & News

$516.56
-38.42 (-6.92 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$507.22
Now: $516.56
$556.31
50-Day Range
$530.66
MA: $579.01
$643.45
52-Week Range
$309.38
Now: $516.56
$648.39
Volume871,108 shs
Average Volume223,184 shs
Market Capitalization$15.41 billion
P/E Ratio4.42
Dividend YieldN/A
Beta1
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More
Bio-Rad Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000
Employees8,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$6.45 per share
Book Value$295.84 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Market Cap$15.41 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$516.56
-38.42 (-6.92 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

How has Bio-Rad Laboratories' stock been impacted by Coronavirus (COVID-19)?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIO stock has increased by 49.4% and is now trading at $516.56.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Bio-Rad Laboratories?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bio-Rad Laboratories
.

What stocks does MarketBeat like better than Bio-Rad Laboratories?

Wall Street analysts have given Bio-Rad Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Rad Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Bio-Rad Laboratories
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings results on Thursday, October, 29th. The medical research company reported $3.00 EPS for the quarter, beating the Zacks' consensus estimate of $1.85 by $1.15. The medical research company had revenue of $647.26 million for the quarter, compared to the consensus estimate of $567.35 million. Bio-Rad Laboratories had a net margin of 147.91% and a return on equity of 3.77%. The company's revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.61 earnings per share.
View Bio-Rad Laboratories' earnings history
.

What price target have analysts set for BIO?

4 brokerages have issued twelve-month price targets for Bio-Rad Laboratories' stock. Their forecasts range from $430.00 to $675.00. On average, they expect Bio-Rad Laboratories' share price to reach $609.20 in the next year. This suggests a possible upside of 17.9% from the stock's current price.
View analysts' price targets for Bio-Rad Laboratories
.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 449,600 shares, an increase of 24.9% from the September 30th total of 360,000 shares. Based on an average trading volume of 157,700 shares, the short-interest ratio is currently 2.9 days. Currently, 2.1% of the company's shares are short sold.
View Bio-Rad Laboratories' Short Interest
.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 70, Pay $2.12M)
  • Mr. Ilan Daskal, Exec. VP & CFO (Age 54, Pay $754.23k)
  • Dr. Andrew J. Last, Exec. VP & COO (Age 60, Pay $825.67k)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 58, Pay $663.07k)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 65, Pay $769.91k)
  • Mr. Ajit Ramalingam, Sr. VP & Chief Accounting Officer (Age 47)
  • Diane Dahowski, Sr. VP of Global Technology & Systems
  • Mr. Timothy S. Ernst, Exec. VP, Gen. Counsel & Sec. (Age 60)
  • Colleen Corey, Sr. VP of Global HR
  • Lee Boyd, Sr. VP of Global Commercial Operations - Asia Pacific

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include Great West Life Assurance Co. Can (27.95%), BlackRock Inc. (5.47%), State Street Corp (3.21%), UBS Asset Management Americas Inc. (1.29%), First Trust Advisors LP (0.99%) and Acadian Asset Management LLC (0.81%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark, John Hertia, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., AQR Capital Management LLC, Artemis Investment Management LLP, Tang Capital Management LLC, KBC Group NV, Fisher Asset Management LLC, UBS Asset Management Americas Inc., and Acadian Asset Management LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Giovanni Magni, Michael Crowley, and Ronald W Hutton.
View insider buying and selling activity for Bio-Rad Laboratories
.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, State of Tennessee Treasury Department, BlackRock Inc., State Street Corp, AJO LP, Voloridge Investment Management LLC, Candriam Luxembourg S.C.A., and Victory Capital Management Inc..
View insider buying and selling activity for Bio-Rad Laboratories
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $516.56.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $15.41 billion and generates $2.31 billion in revenue each year. The medical research company earns $1.76 billion in net income (profit) each year or $7.06 on an earnings per share basis. Bio-Rad Laboratories employs 8,000 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.